Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES BAIN CAPITAL AND BRAVIDA
Mandate

VINGE ADVISES BAIN CAPITAL AND BRAVIDA

June 20, 2013

Vinge and Kirkland & Ellis are advising Bain Capital and Bravida in connection with the refinancing of Bravida, which includes the issue of senior secured floating rate notes in the amount of SEK 1.3 billion and EUR 225 million.

Vinge’s team consists of partners Stefan de Hevesy, Christina Kokko and Peter Bäärnhielm together with associates Robin Dangoor, Paul Dali, Charlotta Järnstedt, Andreas Malmberg, Dain Nevonen and Marie Brommesson.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026